WO2004031242A3 - Protein complexes involved in neurological diseases - Google Patents

Protein complexes involved in neurological diseases Download PDF

Info

Publication number
WO2004031242A3
WO2004031242A3 PCT/EP2003/010110 EP0310110W WO2004031242A3 WO 2004031242 A3 WO2004031242 A3 WO 2004031242A3 EP 0310110 W EP0310110 W EP 0310110W WO 2004031242 A3 WO2004031242 A3 WO 2004031242A3
Authority
WO
WIPO (PCT)
Prior art keywords
complexes
neurological diseases
protein complexes
complexes involved
methods
Prior art date
Application number
PCT/EP2003/010110
Other languages
French (fr)
Other versions
WO2004031242A2 (en
Inventor
Tewis Bouwmeester
Gerard Drewes
David Jackson
Gerd Helftenbein
Markus Schirle
Bernhard Kuester
Carsten Hopf
Original Assignee
Cellzome Ag
Tewis Bouwmeester
Gerard Drewes
David Jackson
Gerd Helftenbein
Markus Schirle
Bernhard Kuester
Carsten Hopf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Ag, Tewis Bouwmeester, Gerard Drewes, David Jackson, Gerd Helftenbein, Markus Schirle, Bernhard Kuester, Carsten Hopf filed Critical Cellzome Ag
Priority to AU2003299206A priority Critical patent/AU2003299206A1/en
Publication of WO2004031242A2 publication Critical patent/WO2004031242A2/en
Publication of WO2004031242A3 publication Critical patent/WO2004031242A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Abstract

The present invention relates to protein complexes involved in cellular processes which have been shown to be critical for the development of various forms of neurological diseases, to component proteins of the said complexes, to fragments and derivatives of the component proteins and to antibodies specific to the complexes. It further relates to methods for use of the complexes and their interacting proteins in, inter alia, screening, diagnosis and therapy, as well as to methods of preparing said complexes.
PCT/EP2003/010110 2002-09-12 2003-09-11 Protein complexes involved in neurological diseases WO2004031242A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003299206A AU2003299206A1 (en) 2002-09-12 2003-09-11 Protein complexes involved in neurological diseases

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP02020497 2002-09-12
EP02020495 2002-09-12
EP02020496 2002-09-12
EP02020497.0 2002-09-12
EP02020495.4 2002-09-12
EP02020496.2 2002-09-12

Publications (2)

Publication Number Publication Date
WO2004031242A2 WO2004031242A2 (en) 2004-04-15
WO2004031242A3 true WO2004031242A3 (en) 2004-08-05

Family

ID=32073831

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/010110 WO2004031242A2 (en) 2002-09-12 2003-09-11 Protein complexes involved in neurological diseases

Country Status (2)

Country Link
AU (1) AU2003299206A1 (en)
WO (1) WO2004031242A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2806816C (en) * 2010-07-28 2018-05-29 Abbott Gmbh & Co. Kg Method for detection of ischemic strokes
GB201309509D0 (en) * 2013-05-28 2013-07-10 Nat Univ Ireland Diagnostic marker for crohn's disease
CN114874339B (en) * 2022-05-27 2023-07-21 清华大学 Protein adhesive, preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001061001A2 (en) * 2000-02-18 2001-08-23 Basf-Lynx Bioscience Ag Novel, central nervous protein, that modulates k+ flows
WO2001083739A2 (en) * 2000-04-28 2001-11-08 Immunex Corporation Human pellino polypeptides
WO2002064736A2 (en) * 2001-01-04 2002-08-22 Myriad Genetics, Inc. Protein-protein interactions
WO2002092626A2 (en) * 2001-05-15 2002-11-21 Cellzome Ag Cleavage and polyadenylation complex of precursor mrna

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001061001A2 (en) * 2000-02-18 2001-08-23 Basf-Lynx Bioscience Ag Novel, central nervous protein, that modulates k+ flows
WO2001083739A2 (en) * 2000-04-28 2001-11-08 Immunex Corporation Human pellino polypeptides
WO2002064736A2 (en) * 2001-01-04 2002-08-22 Myriad Genetics, Inc. Protein-protein interactions
WO2002092626A2 (en) * 2001-05-15 2002-11-21 Cellzome Ag Cleavage and polyadenylation complex of precursor mrna

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAO Z ET AL: "IRAK: A KINASE ASSOCIATED WITH THE INERLEUKIN-1 RECEPTOR", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 271, no. 5252, 23 February 1996 (1996-02-23), pages 1128 - 1131, XP001026471, ISSN: 0036-8075 *
CHEN BING-CHANG ET AL: "Inhibition of interleukin-1beta-induced NF-kappaB activation by calcium/calmodulin-dependent protein kinase kinase occurs through Akt activation associated with interleukin-1 receptor-associated kinase phosphorylation and uncoupling of MyD88", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 27, 5 July 2002 (2002-07-05), pages 24169 - 24179, XP002268505, ISSN: 0021-9258 *
DATABASE EMBL [online] 1 March 2002 (2002-03-01), STRAUSBERG R., XP002268507, accession no. EBI Database accession no. Q8VC03 *
LI SHYUN ET AL: "IRAK-4: A novel member of the IRAK family with the properties of an IRAK-kinase", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 99, no. 8, 16 April 2002 (2002-04-16), April 16, 2002, pages 5567 - 5572, XP002268506, ISSN: 0027-8424 *
MAMIDIPUDI V WOOTEN M W: "IRAK and the atypical PCK interacting protein p62 are critical components in p75-neurotrophin activation of NF-(kappa) B", FASEB JOURNAL (FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY), BETHESDA, US, vol. 16, no. 5, 2002, pages A1196,ABSTRACTNO8881, XP002956846, ISSN: 0892-6638 *
WANG X S ET AL: "MAPKKK6, a novel mitogen-activated protein kinase kinase kinase, that associates with MAPKKK5", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 253, no. 1, 9 December 1998 (1998-12-09), pages 33 - 37, XP002169311, ISSN: 0006-291X *

Also Published As

Publication number Publication date
AU2003299206A8 (en) 2004-04-23
WO2004031242A2 (en) 2004-04-15
AU2003299206A1 (en) 2004-04-23

Similar Documents

Publication Publication Date Title
WO2004009622A3 (en) Protein complexes of cellular networks underlying the development of cancer and other diseases
WO2004013180A3 (en) Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
WO2005012493A3 (en) Anti-cd19 antibodies
WO2004046342A3 (en) Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas
WO2007067730A3 (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
WO2007092640A3 (en) Antibodies that bind par-2
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004092215A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
EP2322551A3 (en) Compositions comprising Anti-IGF-1R Antibodies and Methods for their Production
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2005046709A3 (en) Tgf - beta binding and supported peptides
WO2005003298A3 (en) Surrogate therapeutic endpoint for anti-ctla-4 based immunotherapy of disease
WO2004106380A3 (en) Human-anti-human cd3 binding molecules
WO2005016127A3 (en) Prion-specific peptide reagents
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
WO2002088750A3 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2001064877A3 (en) Human schizophrenia gene
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2004094476A3 (en) Compositions and methods relating to stop-1
WO2004069860A3 (en) Isg15-conjugated proteins
WO2006108051A3 (en) Compositions and methods relating to alzheimer's disease
WO2004066933A3 (en) Compositions and methods for treating cancer using igsf9 and liv-1
WO2004042083A3 (en) Nucleic acid ligands and uses therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP